In addition, evaluation by HTA agencies for reimbursement of anti-PD-1 for stage IIB/C melanoma may be additionally influenced by the lack of direct evidence for OS improvements in stage III melanoma coupled with uncertain association between positive RFS and OS, leading to uncertain societal benefits. Here, PDCD1 is linked to melanoma.